Verastem Inc. Common Stock (VSTM)

About VSTM

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway t…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

102

Website

www.verastem.com

Fundamentals

1-day range

$6.45$6.66

Market cap

$500.00M

P/E (trailing)

—

P/E (forward)

-8.77

EPS (trailing)

$-2.44

Dividend yield

—

Beta

0.29

Avg. volume

2.53M

Forecasts

8 analyst ratings

Verastem Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• VSTM

  Verastem Inc. Common Stock

  $7.22

  ▼ 2.17%
  Market cap $500.00MP/E —
  $3.43$11.25
• ARVN

  Arvinas Inc. Common Stock

  $9.16

  ▼ 0.87%
  Market cap $520.04MP/E 62.96
  $6.97$14.51
• QTTB

  Q32 Bio Inc. Common Stock

  $15.01

  ▼ 7.06%
  Market cap $451.37MP/E 15.71
  $1.62$23.57
• CBIO

  Crescent Biopharma Inc. Common Stock

  $17.74

  ▼ 0.14%
  Market cap $552.33MP/E —
  $8.72$27.41
• SGMT

  Sagimet Biosciences Inc. Series A Common Stock

  $10.55

  ▼ 1.86%
  Market cap $441.53MP/E —
  $4.5$11.15
• PRTA

  Prothena Corporation plc Ordinary Shares

  $9.35

  ▲ 2.86%
  Market cap $436.10MP/E —
  $7.73$11.8
• MPLT

  MapLight Therapeutics Inc. Common Stock

  $12.64

  ▲ 0.80%
  Market cap $569.09MP/E —
  $9.1$40.43

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Mizuho Maintains Outperform on Verastem, Lowers Price Target to $13
  Benzinga · 8/11/2026
• Guggenheim Maintains Buy on Verastem, Lowers Price Target to $12
  Benzinga · 8/7/2026
• Verastem, Inc. (VSTM) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/7/2026
• Verastem, Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/7/2026
• Verastem Q2 Adj. EPS $(0.35) Beats $(0.43) Estimate, Sales $25.078M Beat $23.093M Estimate
  Benzinga · 8/6/2026

• Dan Paterson · August 3, 2026 · Sale

  1.3K @ $5.81
• Dan Paterson · June 22, 2026 · Sale

  20.9K @ $4.18
• Daniel Calkins · June 22, 2026 · Sale

  57 @ $4.13
• Daniel Calkins · June 22, 2026 · Sale

  4.0K @ $4.18
• Michael P. Bailey · May 21, 2026 · Grant

  108.0K
• Karin Anna Tollefson · May 21, 2026 · Grant

  36.0K
• Brian M. Stuglik · May 21, 2026 · Grant

  36.0K
• Michelle Robertson · May 21, 2026 · Grant

  36.0K
• Anil Kapur · May 21, 2026 · Grant

  36.0K
• Paul A. Bunn · May 21, 2026 · Grant

  36.0K
• John Johnson · May 21, 2026 · Grant

  36.0K
• Eric K. Rowinsky · May 21, 2026 · Grant

  36.0K
• Dan Paterson · May 4, 2026 · Sale

  806 @ $5.82
• Daniel Calkins · March 20, 2026 · Grant

  57 @ $5.74

Institutional Ownership

March 31, 2026

Total shares held

80.62M

Total value held

$424.35M

Institutional holders

151